RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep with the broad market rally.
It also appears that the GOP will retain a slight majority in the Senate, thereby greatly diminishing Dems’ power to revamp U.S. healthcare.
NAI is hosting the GCFF Virtual Conference – Diversified Investing Strategies. Featuring over 12 public and private companies representing the newest innovations in healthcare, technology and investment, the event will provide our readers with the most exciting growth opportunities in 2020. Learn more at: https://nai500.com/events/gcff-2020-diversified-invest/.
Novavax (NVAX +2.8%) has signed an agreement with the Australian government to supply 40M doses of the company’s NVX-CoV2373 Covid-19 vaccine candidate. Interim data expected as soon as early Q1 of 2021.
Delivery could start as early as 1H of 2021
To date, Novavax has established various agreements for the supply of NVX-CoV2373 directly to the U.S. and the U.K., Canada, Japan, South Korea and India.
Trading on Nasdaq Capital Market is expected to begin on November 5, 2020.
On transfer, Nasdaq granted the Company its second grace period of 180 days, or until May 3, 2021, to satisfy the $1.00 bid price requirement to maintain listing.
Shares +6% premarket.
The Financial Times reports that AstraZeneca (AZN +6.7%) missed its target of delivering 30M doses of its COVID-19 vaccine, currently dubbed AZD1222, to the U.K. by the end of September.
Lineage Cell Therapeutics (NYSEMKT:LCTX): Q3 GAAP EPS of -$0.05 misses by $0.01.
Revenue of $0.57M (flat Y/Y) beats by $0.01M.